CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities

Luis Chinea, Caroline Hauer, Khushboo Pal, Hannah L. Chang, Isaac S. Chan

Open source

DOI
10.1007/s11523-026-01232-1
Published
2026-08-06
Container
Targeted Oncology
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s11523-026-01232-1,
  title = {CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities},
  author = {Luis Chinea and Caroline Hauer and Khushboo Pal and Hannah L. Chang and Isaac S. Chan},
  year = {2026},
  journal = {Targeted Oncology},
  doi = {10.1007/s11523-026-01232-1},
  url = {https://doi.org/10.1007/s11523-026-01232-1}
}

RIS

TY  - JOUR
TI  - CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities
AU  - Luis Chinea
AU  - Caroline Hauer
AU  - Khushboo Pal
AU  - Hannah L. Chang
AU  - Isaac S. Chan
PY  - 2026
JO  - Targeted Oncology
DO  - 10.1007/s11523-026-01232-1
UR  - https://doi.org/10.1007/s11523-026-01232-1
ER  - 

APA

Chinea, L., Hauer, C., Pal, K., Chang, H. L., & Chan, I. S. (2026). CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities. Targeted Oncology. https://doi.org/10.1007/s11523-026-01232-1

Source records